4.6 Article

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Journal

Publisher

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.09191010

Keywords

-

Funding

  1. Gilead Science France
  2. Janssen-Tibotec
  3. Bristol-Myers Squibb
  4. GlaxoSmithKline
  5. Abbott
  6. Gilead Science
  7. Gilead
  8. Pfizer
  9. Roche
  10. Abott Industries
  11. Jansen-Cilag
  12. Merck Sharp Dohme (MSD)
  13. Merck
  14. Tibotec

Ask authors/readers for more resources

Background and objectives The main aim of this study was determining the risk factors of chronic kidney disease (CKD) in HIV-1-infected patients. Design, setting, participants, & measurements Patients were followed from seven large HIV reference centers in France that maintain prospective databases on HIV-1-infected patients. The main outcome was the time to CKD defined as two consecutive measures of estimated GFR <= 60 ml/min per 1.73 m(2) over >= 3 months. A Cox's model with delayed entry was used to search predictive factors of time to CKD. Results From 1993 to 2006, 349 out of 7378 patients were found to have CKD. Of these, 166 had hypertension, 33 had diabetes, and 26 were antiretroviral therapy nave. Occurrence of acute kidney injury (hazard ratio [HR] = 2.40) and hypertension (HR = 2.39) were strongly associated with an increased risk of CKD. Patients with a durable level of CD4 count >200 cells/mm(3) had a lower risk of CKD (HR = 0.63). Recent exposure to indinavir (HR = 2.03), totenofovir (HR = 1.55), and abacavir (HR = 1.37) were associated with an increased risk of CKD. Past exposure to tenofovir was also associated with an increased risk of CKD (HR = 2.23), and a trend toward significance was observed for past exposure to indinavir (HR = 1.28). Conclusions CKD was not rare in HIV-infected patients and occurs preferentially in HIV-infected patients exposed to certain ARVs, specifically abacavir, indinavir and tenofovir. This requires closer monitoring of renal function in patients exposed to one of these drugs. Clin J Am Soc Nephrol 6: 1700-1707, 2011. doi: 10.2215/CJN.09191010

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available